1. Introduction

Sunitinib mesylate (Sutent®) is a multikinase inhibitor approved by the FDA and EMA for several advanced malignancies. It is classified as a targeted therapy, specifically a tyrosine kinase inhibitor (TKI), with broad activity against receptor tyrosine kinases (RTKs) implicated in tumor growth, angiogenesis, and metastasis. Its use requires careful clinical oversight due to its complex pharmacology, significant adverse effect profile, and the need for monitoring for potentially life-threatening toxicities.

2. Indications & Evidence Base

A. Gastrointestinal Stromal Tumors (GIST)

• Indication: Used in adults with advanced GIST after progression on imatinib or intolerance to imatinib.
• Evidence: The pivotal phase II study by Pardoll et al. (2008, NEJM) demonstrated improved progression-free survival (PFS) and overall survival (OS) versus placebo in this population (NEJM 2008;358:1601–1610).
• Patient Selection: Only for well-differentiated, unresectable or metastatic GISTs.

B. Advanced Renal Cell Carcinoma (RCC)

• Indication: Adjuvant therapy after nephrectomy in patients at high risk of recurrence.
• Evidence: The SUTENT trial (2010, Lancet Oncology) showed improved disease-free survival (DFS) and OS compared to placebo (Lancet Oncol 2010;11:101–108).
• Monitoring: Regular assessment for hypertension, renal function, and skin toxicity is essential.

C. Pancreatic Neuroendocrine Tumors (pNETs)

• Indication: For advanced, well-differentiated pNETs that are unresectable or metastatic.
• Evidence: The SONIA trial (2012, Lancet Oncology) showed improved PFS (Lancet Oncol 2012;13:1087–1096).
• Patient Selection: Only for patients with progressive, unresectable, or metastatic disease.

3. Mechanism of Action

Sunitinib is a small molecule that competitively inhibits the ATP-binding sites of multiple RTKs, including:

• Platelet-Derived Growth Factor Receptors (PDGFRα/β)
• Vascular Endothelial Growth Factor Receptors (VEGFR1, 2, 3)
• KIT (critical in GIST)
• FMS-like tyrosine kinase-3 (FLT3)
• Colony Stimulating Factor Receptor Type 1 (CSF1R)
• RET

By inhibiting these receptors, sunitinib disrupts tumor angiogenesis, proliferation, and metastatic spread (Druker et al., Lancet 2000;356:549–556).

4. Dosage & Administration

A. Standard Adult Dosing

• Metastatic RCC, Unresectable GIST, pNETs:
  • 50 mg PO once daily for 4 weeks, followed by a 2-week break (6-wk cycle).
  • Dose adjustments: May be reduced in increments of 12.5 mg based on tolerability.
  • Minimum dose: 25 mg/day; Maximum: 75 mg/day.
• pNETs: 37.5 mg once daily, continuous dosing.

B. Administration

• Route: Oral
• Food: Can be taken with or without food.
• Avoid grapefruit juice (inhibits CYP3A4, increasing sunitinib exposure).
• Missed dose: Take as soon as possible unless >12 hours have passed; do not double dose.

5. Pharmacokinetics & Metabolism

• Bioavailability: ~60% (highly variable)
• Metabolism: Primarily via CYP3A4
• Half-life: 30–50 hours
• Renal excretion: ~70% unchanged; caution in renal impairment

6. Adverse Effects & Monitoring

A. Serious Toxicities

• Hypertension: Occurs in up to 60%; monitor BP regularly (NCCN Guidelines)
• Hematologic toxicity: Thrombocytopenia, anemia
• Gastrointestinal: Diarrhea, nausea, abdominal pain
• Skin: Hand-foot syndrome (palmar-plantar erythrodysesthesia), rash, ulceration
• Cardiac: QT prolongation, heart failure
• Hepatic: Elevated transaminases, rare hepatotoxicity
• Renal: Proteinuria, renal dysfunction
• Ocular: Cataracts, blurred vision, retinopathy
• Metabolic: Hyperglycemia, hypoglycemia (rare)
• Bone marrow suppression

B. Dermatologic Toxicity

• Skin reactions: Occur in up to 60%; grade 3–4 in ~10% (NCCN Guidelines)
• Management: Dose interruption, topical steroids, dose reduction if severe.

C. Cardiac

• QT prolongation: Risk increased with electrolyte disturbances (hypokalemia, hypomagnesemia), concomitant QT-prolonging drugs.
• Monitoring: Baseline and periodic ECG; correct electrolytes.

7. Drug Interactions & Comorbidities

A. Drug Interactions

• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): Increase sunitinib levels.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): Decrease efficacy.
• Diuretics: Risk of hypokalemia and QT prolongation.
• NSAIDs/ACE inhibitors: May increase risk of renal impairment.

B. Comorbidities to Screen For

• Cardiac disease: History of arrhythmia, heart failure, ischemic heart disease
• Renal impairment: Baseline creatinine, eGFR monitoring
• Liver disease: Assess LFTs before and during therapy
• Hypertension: Monitor closely

8. Special Populations

A. Pregnancy

• Contraindicated: Risk of fetal harm (teratogenicity).
• Contraception advised: Both men and women for at least 6 months after last dose.

B. Geriatric Patients

• No formal dose adjustment, but increased risk of toxicity; monitor closely.

C. Hepatic/Kidney Impairment

• Moderate impairment: Use with caution, consider dose reduction.
• Severe impairment: Not recommended unless life-threatening and no alternatives.

9. Storage & Handling

• Store at 20–25°C (68–77°F); excursions allowed to 15–30°C (59–86°F).
• Protect from moisture and light.

10. Clinical Pearls for Pharmacists

• Baseline labs: CBC, LFTs, renal function, electrolytes, BP, ECG.
• Ongoing monitoring: BP, renal function, skin integrity, cardiac symptoms, ocular exam as needed.
• Patient education: Emphasize adherence, reporting of side effects promptly, and avoidance of grapefruit.
• Drug interactions: Review all medications (including OTC and supplements).
• Supportive care: Prophylactic antiemetics for nausea, antidiarrheals, skin care regimens.

11. Summary Table

References

• Pardoll DM et al., NEJM 2008; Sunitinib in advanced GIST.
• SUTENT trial, Lancet Oncology 2010/2012.
• NCCN Guidelines v.2024: Renal, GI Malignancies, Skin Toxicity.
• FDA Prescribing Information for Sutent® (Sunitinib Mesylate).

In summary: Sunitinib is a potent, multi-targeted kinase inhibitor with significant clinical benefit in select advanced cancers but requires vigilant monitoring for serious toxicities and careful management of drug interactions. Pharmacists play a critical role in optimizing therapy, preventing adverse events, and supporting patient adherence.